Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIPK2 | Q9H2X6 | 8/20 | 0.77 |
| ▸ | CSNK2A2 | P19784 | 9/20 | 0.51 |
| ▸ | CSNK2B | P67870 | 9/20 | 0.51 |
| ▸ | CSNK2A1 | P68400 | 7/20 | 0.50 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30771577 | 1.00 | HIPK2 (0.77) | HIPK2CSNK2A2CSNK2BCSNK2A1NCOA3 | |
| SCHEMBL28442922 | 0.99 | HIPK2 (0.75) | HIPK2CSNK2A2CSNK2BCSNK2A1NCOA3 | |
| SCHEMBL20704231 | 0.87 | HIPK2 (1.00) | HIPK2CSNK2A1NCOA3 | |
| SCHEMBL25616248 | 0.81 | HIPK2 (0.61) | HIPK2CSNK2A2CSNK2BCSNK2A1NCOA3 | |
| SCHEMBL30771546 | 0.79 | HIPK2 (0.75) | HIPK2CSNK2A2CSNK2BCSNK2A1PARP1 | |
| SCHEMBL20718579 | 0.79 | HIPK2 (0.75) | HIPK2CSNK2A2CSNK2BCSNK2A1PARP1 | |
| SCHEMBL20704081 | 0.79 | HIPK2 (0.75) | HIPK2CSNK2A2CSNK2BCSNK2A1PARP1 | |
| SCHEMBL20718400 | 0.79 | HIPK2 (0.57) | HIPK2CSNK2A2CSNK2BCSNK2A1PARP1 | |
| SCHEMBL30771535 | 0.79 | HIPK2 (0.75) | HIPK2CSNK2A2CSNK2BCSNK2A1PARP1 | |
| SCHEMBL30771554 | 0.79 | HIPK2 (0.57) | HIPK2CSNK2A2CSNK2BCSNK2A1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11932606-B2 | Anti-cancer/anti-fibrosis compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-03-19 | — | — | US | claimed |
| CN-111447931-B | Anticancer/antifibrotic compounds | 加利福尼亚大学董事会 | 2024-01-26 | — | — | CN | claimed |
| US-20230192621-A1 | Anti-Cancer/Anti-Fibrosis Compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-06-22 | — | — | US | claimed |
| US-20230192621-A1 | Anti-Cancer/Anti-Fibrosis Compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-06-22 | — | — | US | disclosed |
| US-20230192621-A1 | Anti-Cancer/Anti-Fibrosis Compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-06-22 | — | — | US | disclosed |
| WO-2019028059-A1 | ANTI-CANCER/ANTI-FIBROSIS COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11932606-B2 | Anti-cancer/anti-fibrosis compounds | CCL11, MMP1, HDGF | HIPK2 2797/4885CSNK2A2 4047/4885CSNK2B 4024/4885 |
| US-20230192621-A1 | Anti-Cancer/Anti-Fibrosis Compounds | CCL11, MMP1, HDGF | HIPK2 2797/4885CSNK2A2 4047/4885CSNK2B 4024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.